Candida Auris: Ignore it and Other Emerging Pathogens at Your Own Risk! 

Wednesday, May 17, 2023    11:00AM-12:15PM (ET), including Q&A    

Most treatments for emerging and potentially dangerous pathogens are failing. Repeated warnings about the likelihood of a pandemic event worse than COVID-19 have been issued by governing bodies, research organizations and prominent leaders in the healthcare arena, but coordinated responses have yet to be developed. This Salon, with leaders in public health, clinical practice, research, and the government, will provide answers to meeting the pathogen threat and first steps to defend against it from some of the most highly regarded people in the quest to meet the challenge of emerging pathogens. 

Please click here to view on demand.

Biographies:

Wednesday, May 3, 2023   11:00AM-12:15PM ET, including Q&A 

Market Access and Valuation: Key Considerations for Multi-Indication Products   

Join a distinguished panel of experts for a robust discussion on pricing and deal valuation dynamics for multi-indication products.  The discussion will focus on the issues that potential commercialization partners, acquirers, and capital providers will examine when evaluating a multi-indication product as well as platform products for deal valuation purposes.  This panel of experts will share their experiences as CEOs, BD, and Market Access leaders, Country Managers and royalty investors from companies including Alexion, DRI Capital, Genentech, Genzyme, GSK, and Pfizer. 

Please click here to view on demand.

Biographies:

Ted Haack, Judy Campagnari, Elizabeth Jeffords, Diane Munch, Jeannie Rojas

February 8, 2023  11:00-12:15PM ET Including Q&A

Fundraising in 2023: The Post JP Morgan/Biotech Showcase Outlook for Early-Stage Companies

Now that we are back from what is arguably the most important week in the life sciences calendar, we want to know what the sentiment is for fundraising in 2023 and will it change in 2024. Should private companies focus on cash preservation and out-licensing programs? What will 2024 bring?  Is there a consensus that management can use to guide them?   

Please click here to view on demand.

Biographies:

Marian Nakada, PhD, Ed Saltzman

November 30, 2022 11:00-12:15PM ET Including Q&A

Raising Money In This Market: Can It Be Done?

Yes, it can, but it is not easy. VCs share their insights about how to navigate and survive this market now and how to position your company to raise money when the market returns to the next new normal. Join this conversation among VCs as they discuss the advice they give their portfolio companies about getting through the choppy waters. 

Please click here to view on demand.

Biographies:

Kimberly Ha, Maha Katabi, PhD, Nina Kjellson, Marian Nakada, PhD

Runway Extension in Difficult Times

August 31, 2022 11:00 - 12:15PM ET (Includes Q&A)

Demy-Colton Virtual Salon Series brings cutting-edge insights from key opinion leaders in the life sciences and digital health industry. For the next Virtual Salon, Demy-Colton has partnered with Biotechgate Digital Partnering. All participants also get complimentary access to one week of virtual partnering with 1000+ participants from all around the globe.

Please click here to view on demand.

Biographies:

Lesley Stolz, Dawn Bell, Philippe Lopes-Fernandes, Uciane Scarlett

Biotechnology Midyear Outlook

Global industries and economies continue on their wild ride, sparked from the pandemic, which thrusted biotechnology center stage during the development of vaccines and therapies. However, sentiment has cooled, driven by a convergence of complex factors, making identifying the next wave of emerging risks and opportunities an acute challenge.
Armed with world class pharmaceutical industry, company, drug development, and financial data, Bloomberg Intelligence analysts join Demy-Colton to discuss the data-driven outlook for the biotech sector, for the balance of the year.
Topics of discussion:

• Key themes to watch
• Overall sector performance
• Inflation impact
• Key biopharma 2H catalysts
• Company sales & margin outlook
• Merger & acquisition watch outlook
• Government & policy regulatory outlook

Please click here to view on demand.

Biographies:

Barbara Ryan, Marc Engelsgjerd, Michael Shah, Duane Wright

U.S. Market Access Strategy at the Clinical Stage for All Companies Considering a Launch:  A Three-Part Series

The complexity of the U.S. market access landscape means that proving safety and efficacy is no longer a guarantee of commercial success. This three-part series will provide you with the basics of government and commercial payer rules, walk through hypotheticals that bring those rules to life, and prepare you for the market’s evolving focus on value-delivery. At the end of the series, you will understand why your market access strategy can and should start before the initiation of your Phase IIIs, have identified early-stage steps to de-risk those variables with the potential to constrain market access later, and why you should be prepared for investors to ask you these same questions. This series will benefit any company new to the U.S. market, or looking to launch in the U.S.

Part 3 of 3: Future-Proofing: How to Prepare a Value-Based Market Access Strategy

Market access considerations continue to evolve in the highly dynamic U.S. market. With an increasing focus on value delivery, Part 3 will discuss the different ways to measure and demonstrate value, the interplay between FDA and CMS on such value propositions, and strategies for payer engagement.

Salon Resource:

Market Access Strategy Part 3 Handout

Please click here to view on demand.

Biographies:

Alice Valder Curran, Michael Rothrock, Peter Rubin, Lowell Zeta

U.S. Market Access Strategy at the Clinical Stage for All Companies Considering a Launch:  A Three-Part Series

The complexity of the U.S. market access landscape means that proving safety and efficacy is no longer a guarantee of commercial success. This three-part series will provide you with the basics of government and commercial payer rules, walk through hypotheticals that bring those rules to life, and prepare you for the market’s evolving focus on value-delivery. At the end of the series, you will understand why your market access strategy can and should start before the initiation of your Phase IIIs, have identified early-stage steps to de-risk those variables with the potential to constrain market access later, and why you should be prepared for investors to ask you these same questions. This series will benefit any company new to the U.S. market, or looking to launch in the U.S.

Part 2 of 3: Making It Real: What Does an Early-Stage Market Access Strategy Look Like?

Using the foundations covered in Part 1, Part 2 will walk through a series of hypotheticals that demonstrate why and how developers can create a market access strategy early in the clinical development process, including strategies for clinical trial design, likely investor inquiries, and competitive positioning.

Salon Resource:

Market Access Strategy Part 2 Handout

Please click here to view on demand.

Biographies:

Alice Valder Curran, Tess Cameron, Adrienne Ellman, Lynn Mehler

U.S. Market Access Strategy at the Clinical Stage for All Companies Considering a Launch:  A Three-Part Series

The complexity of the U.S. market access landscape means that proving safety and efficacy is no longer a guarantee of commercial success. This three-part series will provide you with the basics of government and commercial payer rules, walk through hypotheticals that bring those rules to life, and prepare you for the market’s evolving focus on value-delivery. At the end of the series, you will understand why your market access strategy can and should start before the initiation of your Phase IIIs, have identified early-stage steps to de-risk those variables with the potential to constrain market access later, and why you should be prepared for investors to ask you these same questions. This series will benefit any company new to the U.S. market, or looking to launch in the U.S.

Part 1 of 3: The Foundation: The Basics of Market Access and Why They Matter Before Phase IIIs

This first session will provide a foundation in the government and commercial payer landscape in relation to coverage, reimbursement, and pricing, and how those considerations can have a real-time impact on commercialization strategy. While there are a number of straightforward business considerations relevant to commercialization, the focus of this discussion will be legal and policy considerations, which typically are less readily known to biotechs at this earlier stage of drug development.

Salon Resource:

Market Access Strategy Part 1 Handout

Please click here to view on demand.

Biographies:

Alice Valder Curran, Kave Niksefat, Beth Roberts

Getting to the Next Normal: A Roadmap for Living with COVID

To reach the next normal, we must implement a comprehensive and coordinated roadmap that addresses this pandemic and develops the capacity to confront future biosecurity threats. The shift to the next normal today should not induce complacency, inaction, or premature triumphalism.

Please click here to view on demand.

Biographies:

Sheryl Gay Stolberg, Rick A. Bright, PhD, Ezekiel J. Emanuel, MD, PhD, Michael T. Osterholm, PhD, MPH

Beyond the Business Pitch at JP Morgan: Key issues for emerging companies and investors in 2022

Finding the right investor who shares your passion for the mission and the sense of urgency to meet the objectives is key. JP Morgan and Biotech Showcase are virtual this year. This authoritative panel will explore and discuss how to make the most of your time at JP Morgan & BTS now that it is virtual, getting through to the investors, and key issues to consider going into 2022.

Please click here to view on demand.

Biographies:

Kristin Connarn, David de Graaf, Kyp Sirinakis, Clifford Stocks, Andrew Strong

Biotech Companies Flourish or Fail by Their Data: How to Improve Your Outcomes

Good data management is foundational for every successful biotech company. Data must be clean and reproduceable to successfully attract potential partners and investment dollars. This panel of experts will explore how start-ups, with limited resources, can put structures in-place to successfully manage their data and position themselves for regulatory filings, financings, deal-making, etc.

Please click here to view on demand.

Biographies:

Robert J. Schneider, PhD, Barry Bunin, PhD, Amy Ripka, PhD, Chris Vlahos, PhD

Three Strategies For Attracting Early-Stage Investment
Nearly 80 percent of the new biopharmaceutical projects in development are originating in academia and small-to mid-sized companies. These emerging companies have many challenges in furthering their development of new and exciting projects. Whether a company seeks to out-license, commercialize a compound, or position itself for acquisition, success often depends on early investments. These investments can come from fully integrated pharmaceutical companies and/or venture capitalists (VCs). And, ultimately, the company’s success in securing investment can mean the development of new treatments for the patients who need them most.

How can biotech companies plan their early development strategy to simultaneously position themselves for investment and address the needs of regulators? This panel of industry experts from Parexel Biotech, Health Advances, Johnson & Johnson Innovation, and others will discuss what investors look for and what biotechs can do early in their development to get ahead.

Please click here to view on demand.

Biographies:

Skip Sands, MD, Marian Nakada, PhD, Rito Bergemann, MD, PhD, Balazs Felcsuti

A Billion Dollar Decision – to Launch or Out-License in Europe?

European commercialization can at first sight, appear a little daunting. 30 EAA countries (European Economic Area) plus UK and Switzerland, a population of 370 million, multiple regulatory systems, different reimbursement environments and labor laws, as well as a melting pot of languages and culture. That is why this salon is a must for any CEO considering European commercialization as a strategic option.

With success the rewards of going it alone can be stellar in terms of increased access to your medicines for patients beyond the US and the potential to enhance your market cap exponentially.

The salon draws on the current experience of senior Biotech leaders, highlighting some of the key decision areas including location for the European HQ, timing, phasing and cadence of roll out and perhaps most importantly, the bear traps to avoid!

Please click here to view on demand.

Biographies:

Sean Morgan-Jones, Barry Greene, Stephanie Léouzon, David Meeker, Anant Murthy

Ophthalmic Drug Delivery: Eye on Innovation
Innovative biotech companies are racing to develop unique drug-delivery systems and agents that overcome the many obstacles that have limited the treatment of serious and increasingly common eye problems. Our panelists will outline the trajectory of this industry’s growth and give an overview of the technologies that are advancing it. Many new ocular drug-transport systems and formulations are being designed as noninvasive, early, and more patient-friendly treatments. Our panelists will also provide insight into bringing these treatments from lab to clinical study and market.

Please click here to view on demand.

Biographies:

Laura Randa, Kerrie Brady, Jeffrey L. Cleland, PhD, Lloyd Diamond, Mina Sooch

Fundraising Strategies for European Biopharma Companies

Fundraising for European biopharma companies, especially those that are advancing programs into the clinic, has always been challenging and limiting because of the nature of European public markets. But times may be changing. It appears that the advent of virtual fundraising may be bringing European innovators closer to sources of ex-EU public and private capital. Is this trend real and will it stick? Where does non-dilutive funding fit? Is listing on NASDAQ the answer? What other tools should a CEO and their management team consider as they advance their assets?

Please click here to register.

Biographies:

Nooman Haque, Antonin de Fougerolles, PhD, Denise Scots-Knight, PhD, Tim Knotnerus, 
Steffen Schuster, Martin Welschof, PhD

SPECIAL UPCOMING CHALLENGE:

Humans vs Machines: The Trial Prediction Challenge Series
First Installment

June 30 11:00 - 12:15 PM ET, WITH LIVE Q&A

A first-of-its kind competition: A team of humans will face off against a machine powered by AI to predict multiple mid-stage clinical trial results. Drug development is risky. How do we prioritize? Recent advances in human and machine predictions show great promise, but who is better: humans or machines? The Humans are represented by Diviner and the machines are represented by Molecular Health. This will be the first of four quarterly events. Each quarter contestants will predict several trial outcomes, with industry experts discussing the results, debating what success looks like, and determining winners. 
Who do you think will win?

Please click here to view on demand.

Biographies:

Moderator:

• Ly Nguyen-Jatkoe, Executive Director, Pharma Custom Intelligence, Informa

Panelists:

• Daniel Chancellor, Director, Thought Leadership, Informa Pharma Intelligence
• Mark Gordon, Founder & CEO, Diviner
• Matthias Kopf, PhD, Head of Product Management, Molecular Health GmbH
• Daniel Mytelka, PhD, Head of Methodology, Diviner
• Friedrich von Bohlen, Co-Founder & CEO, Molecular Health GmbH

Psychedelics Get Serious

No longer are psychedelics the purview of the counterculture, they are going mainstream. Depression, anxiety, pain, addiction, PTSD and other mental health disorders have been intractable and untreatable – until now. Psychedelics have demonstrated their clinical efficacy in treating disorders that affect thousands of people. While they are going mainstream, there are still a number of hurdles to overcome including IP protection and FDA/EMEA approval pathways.  There is light at the end of this “tunnel.” This is the dawn of a new era of therapeutics.

Please click here to view on demand. 

Biographies:

Walter Greenleaf, Adam Gazzaley, Charlie Hartwell, Ronan Levy, Ekaterina Malievskaia, 
Berra Yazar-Klosinski

Investing at the Speed of Innovation

Biotech innovation is moving faster than ever. Cell therapies, gene therapies, and programs aimed at newly understood targets are moving from laboratories to patients at an unprecedented pace. In turn, investors must make ever larger bets on innovations at an earlier stage and with less validating evidence. In this session, we will talk with leading investors and successful innovators to learn how they decide what technologies are going to make it and which are just too early. The rapidly emerging landscape for adeno-associated virus (AAV) based gene therapy will be discussed as a case study where billion-dollar bets are being made despite remaining technical hurdles and development uncertainty. 

Salon resource:

Triangle Insights Group: Betting on Hide and Seek with AAV

Please click here to view on demand.

Biographies:

Christopher Apolito, Sarah Jims, Mike Dombeck, Geoff Glass, Thomas Mathers, Joe Zenkus

Strategic Pricing for Optimal Valuation

This session will help leaders think through key pricing issues that will impact their pivotal trials for commercialization, first product launch and business development activities. We will discuss various issues, including taking a country-level perspective, avoiding optimism bias, investing in payer-relevant endpoints, risk mitigation, and why payer research isn’t always the best answer. If you’re a pre-commercial company leader preparing for your first product launch, investing in a new therapeutic area and seeking commercialization partners, this will be a great session for you.

Please click here to view on demand.

Biographies:

Ted Haack, Judy Campagnari, Jessica Martinez, Dennis Purcell, Denise Scots-Knight

VC Trends in Healthcare Investing: The Power of Convergence

Leading VC investors will discuss how advances in AI and machine learning, nanotechnology, optics, quantum physics, and advances in engineering are transforming the life sciences industry. Learn how technology-driven convergence will both disrupt and benefit pharma and biotech. These VC partners will discuss why convergence is a critical component for innovation.

Convergence is the integration of engineering, physical sciences and life sciences. Learn about how funding startups that embrace a convergence environment - interdisciplinary teams and scientists that address major challenges within the life sciences - are accelerating drug development and are the key to solving major challenges such as current manufacturing bottlenecks in cell therapy research. Panelists will also discuss case studies and startups showcasing “convergence in action,” from digital health to biotech.

Please click here to view on demand.

Biographies:

Kimberly Ha, Ann DeWitt, Alex Morgan, Benjamin Quiroga

The Biotech SPAC-tacular: Reshaping the way healthcare thinks about funding
In the past 12-16 months, special purpose acquisition companies, better known as "SPACs" have been making headlines for their high profile, value, and sometimes very sudden entrance to the public markets. Investor interest in biotech & pharma remains hot, whether via SPACs or other funding models, which begs the question: what's driving all the action, and what does it mean for biotech & pharma companies?

Please click here to view on demand.

Salon resource:
Biotech SPAC-Tacular Validates the Future for Quality SPACs

Biographies:

Ann-Hunter Van Kirk, Ali Satvat, Brent Saunders, Kevin Sheridan

Sepsis: A critical healthcare burden needing rapid diagnoses to improve patient outcomes

The mortality rate of sepsis patients increases by as much as 8% each hour proper treatment is not started. Sepsis costs the US healthcare system $62 billion and leads to 270,000 deaths annually. Current diagnoses are inadequate – they take too long and sepsis patients do not have time. Furthermore, they are often wrong. This discussion will focus on the burden of sepsis and how we need to change the paradigm.

Salon resource:

Sepsis Alliance: Sepsis Tech brochure

Please click here to view on demand.

Biographies:

Sara Jane Demy, Rick Bright, Prabhavathi Fernandes, Thomas Heymann, Ciara Kennedy, PhD, 
John J. Sperzel III

Targeting mRNA: The New Frontier of Tailored Therapeutics

Targeting mRNA is rapidly emerging as a promising strategy to hit a range of previously ‘undruggable’ biological targets. New classes of small molecules have recently been described that alter mRNA translation and stability, either by modulating mRNA itself (mRNA epigenetics), or by targeting mRNA splicing or translation. These revolutionary new approaches offer ‘tuneable’ specificity ranging from all mRNAs down to individual mRNAs. Development of these new drug classes has the potential to lead to therapeutic interventions that can be tailored for specific diseases and disorders. 

 Come hear from a panel of biotech and pharma experts on: 

• New developments in mRNA targeting
• Challenges and opportunities
• What pharma may look for to partner

Salon resources:

Pullan Consulting  WEHI Drug Discovery Capabilities 2021

Please click here to view on demand.

Biographies:

Linda Pullan, PhD, Robert A. Copeland, PhD, Joan Heath, PhD, Carolyn Ng, PhD, Jennifer C. Petter, PhD, David Segal, PhD

Gain Your Commercial Edge: Define your value story early

In this Virtual Salon, industry leaders will discuss how they’ve pivoted to create and evolve a “value story” throughout the clinical development and commercial planning processes. Biotech executives have always had an exquisite level of focus on the clinical and regulatory hurdles associated with drug development. Their shift to thinking about the “Value Story” or “Third Hurdle” as it is often described, often comes relatively late in the drug development commercialization process. 
Furthermore, the incoming administration’s focus on therapeutic pricing and access may fundamentally change the way in which patients seek and access healthcare. The discussion will focus on how to navigate the barriers and play to win as the game changes with respect to demonstrable value. 

Salon resources:

Peter Pitts: The Value Equation: A Journey Through the Innovation Ecosystem in the Time of Covid
Triangle Insights Group: PMA Capabilities
Triangle Insights Group: Why the Medicare Specialty Threshold Should Not Drive Pricing Strategy

Please click here to view on demand.

Biographies:

Gautam Aggarwal, Judy Campagnari, Wills Hughes-Wilson, Lorenz Muller, Peter Pitts

The New Alchemy of Investing In Health

Health is undergoing fundamental change. Health care was all about disease, drugs, hospitals and payers. Today we are already moving from disease to prevention. From institutional to individual focus. Health is becoming increasingly personal and the future will look utterly unlike the past. Every aspect of bioscience, medicine and care is about to be revolutionized by a plethora of new possibilities and choice. In this session, investors at the forefront of health transformation talk about the new alchemy of health investing. If the old approaches are increasingly challenged, where do investors seek huge success now?

Please click here to view on demand.

Biographies:

Mike Edelhart, Alexandra Bause, PhD, David Giampaolo, Harald Stock, PhD

How U.S. Policy and Trends Will Shape Healthcare in 2021

2021 promises to be an eventful year for the biopharma industry as Covid-19 vaccines should be rolling out and the policy implications of a new U.S. Presidential administration become clear. Bloomberg Intelligence analysts will share their outlook for the year ahead, including a discussion of key pandemic, sector performance, drug development and healthcare policy themes.

Please click here to view on demand.

Biographies:

Beth Halpern, Marc Engelsgjerd, Sam Fazeli, Brian Rye

COVID-19: Surprising Cardiac Findings & Concern about the Potential Impact

The causative agent of COVID-19, SARS-CoV-2 virus, appears to lead to a multi-system disease that affects the human host widely beyond the respiratory tract.  Acute cardiovascular complications include myocarditis, myocardial infarction, arrhythmia and cardiac arrest.  Case-mortality rate is up to 5-fold higher for those with pre-existing cardiovascular diseases. 

In early reports, detectable cardiac changes are seen in up to 70+% of patients post clinical recovery, including those who have recovered from mild COVID, and young and athletic people with no co-morbidities.  This has potentially enormous implications for long-term cardiovascular health globally given the 50 million world-wide reported cases to date.  We face significant challenges in the diagnosis, monitoring, and treatment of the potential long-term cardiac complications of COVID-19.

Please click here to view on demand.

Biographies:

Sara Jane Demy, Bob S. Hu, Prof. Eike Nagel, Eric Topol

Metabesity: A Healthcare Burden on the Rise

Metabesity, a constellation of the major chronic diseases with metabolic roots affecting an aging population, is on the rise globally. Its societal burden, a mix of chronic, non-communicable diseases, is staggering and growing.

Please click here to view on demand.

Biographies:

Emi Gonzalez, John L. Brooks III, Tomas Landh, Christopher Lento, Komathi Stem

Bioelectric Medicine: Sparking Innovation in Healthcare

Electricity as a therapeutic has been used to re-right heartbeats, to stimulate nerves, neurochemicals and cellular regeneration. Today there is a surge of new medical devices being developed and new bioelectrical treatments for everything from treating a host of CNS diseases to cancer and diabetes. This panel of experts will discuss recent research, the favorable regulatory environment and new business models around the electrifying new wave of potential for bioelectrical therapeutics.

Please click here to view on demand.

Biographies:

Beth Rogozinski, Paolo Cassano, Juan-Pablo Mas, Renee Ryan

The Fusion of technologies: the lines are blurring between physical, digital and biological sciences

Interviewer:

• Art Pappas, Managing Partner, Pappas Capital

Please click here to view on demand.

Biographies:

Art Pappas, Amy Abernethy

Women’s Health Moves Mainstream – Rapid Growth Meets Underserved Market

The rapidly growing “Femtech” market is expected to grow to $50B by 2025. Hear from this group of leading private company CEOs, who are heading up innovative advances in technology, that could change the way women's health is treated. The panelists will share perspectives on high-potential investment areas within the space. Learn how these CEOs secured their initial capital and scaled, and hear them discuss how to build better research, policy, data, and care delivery capabilities to achieve venture-level exits and personalized healthcare for half of the global population.

Please click here to view on demand.

Salon resources:

Frost and Sullivan Femtech Executive Summary Links of Interest from Mylene Yao 
Mycovia Corporate Overview Shape the Next Wave of Femtech Innovation

Biographies:

Christina Jenkins, Patrick Jordan, Katherine Ryder, Surbhi Sarna, Mylene Yao

Fireside Chat with Mike Gaito, Global Head of Healthcare Investment Banking, JP Morgan

Moderator: 

• Dennis Purcell, Founder, Aisling Capital

Please click here to view on demand.

Biographies:

Dennis Purcell, Michael Gaito

Futurescaping Of Oncology

Futurescaping of Oncology will explore forward-looking, key, therapeutically relevant technology advances that could change the way we treat cancer. Three novel platforms will be discussed including endogenous reprogramming, targeting RNA, and targeting undruggable protein targets. These new technological innovations were chosen to reflect a range of approaches, risks, degrees of validation, and complexity of engineering. These platforms are excellent examples of higher-level technologies that will take cancer therapies to the next level.

Please click here to view on demand.

Biographies:

Jeffrey Bockman, Jake Becraft, Jennifer C Petter, Arthur T Sands

Lessons from Bergamo: Discoveries in Treating Critically-ill COVID-19 Patients

By now it's clear that many people with COVID-19 severe enough to put them in a hospital face a long recovery. The virus ravages the lungs and other organs in multiple ways. Direct invasion of cells can damage or destroy them and drive massive inflammation throughout the body. Autopsies commonly show arterial thrombosis and severe endothelial damage. Endothelial damage, which can play an early and central pathogenic role in acute respiratory distress syndrome (ARDS) and thrombosis, activates the lectin pathway of complement.

Join Sara Jane Demy, CEO & Founder of Demy-Colton, as she moderates a hematology KOL panel to discuss lessons learned from the front-line in treating critically ill patients in Bergamo, Italy.

This panel will discuss novel pathways in the fight against COVID-19, in particular, the central role of endothelial injury, activation of the complement system and the lectin pathway and thrombosis development in COVID-19.

Please click here to view on demand.

Salon resources:
Slide Decks:
Dr. Laurence slide deck, Dr. Perales slide deck Dr. Rambaldi slide deck
Other resources:
Treatment with the Lectin-Pathway Inhibitor Narsoplimab TR COVID-19 paper 
Clinical & Experimental Immunology MASP2
 

Biographies:

Sara Jane Demy, Jeffrey C Laurence, Miguel-Angel Perales, Alessandro Rambaldi

In Vivo Gene Therapy: Personalizing the Ultra-Rare and Scaling-Up for Chronic Disease

Advanced therapeutics, including gene and call therapies, have emerged as significant FDA/EMA approved therapies for several ultra-rare genetic disorders and advanced malignancies.  In the next couple years, many more will be seeking registration using validated in-vivo and ex-vivo gene transfer and modification platforms (AAV, lentiviral, oligonucleotides, gene editing nucleases, etc.) earning a significant role in the healthcare pharmacopeia.  However, while hurdles such as regulation, manufacturing costs, logistics, and reimbursement have limited patient access, pioneers in the gene therapy sector have been reshaping what healthcare delivery looks like for the next wave of innovators. This BioFuture Salon will discuss the state of the art and potential for gene therapies to become more “drug-like” and scalable for either the personalized ultra-rare or more common chronic disorders.

Please click here to view on demand.

Biographies:

Michael C. Rice, Faraz Ali, Geoff McDonough, Sapan Shah

Alzheimer's: Like a Tsunami, by the time you see it, it is too late

Alzheimer’s disease is a relentless, fatal disease creating a health crisis for patients, families and nations. If we can’t stop it, the cost to society will be great. Global thought leaders have aligned around a goal to have a treatment that will slow the progression of the disease by 2025. While there have been no positive late-stage studies of investigational medicines in the last decade, the scientific advancement and understanding of AD progression and diagnosis has shifted our knowledge of the disease significantly and led to increased drug development targeting populations in the earliest stages of disease. This evolving scientific understanding of Alzheimer’s disease and the promise that treating earlier than we do today will translate to better patient outcomes.

Please click here to view on demand.

Biographies:

Sara Jane Demy, Phyllis Barkman-Ferrell, Dr. Mylea Charvat, Dr. Howard Fillit, Prof. Craig Ritchie

Drugging the Undruggable:The Power of Artificial Intelligence

It is estimated that up to 85% of the human proteome is currently "undruggable." These proteins lack easy-to-find pockets where therapeutics can bind. A wave of biotech companies with new technologies have arrived to tackle the problem of overcoming these most elusive drug targets.

Please click here to view on demand.

Biographies:

Sara Jane Demy, Robert J. Schneider, Abraham Heifets, Marian Nakada, Noam Solomon, Alice Zhang

The Future of Healthcare: Innovation, Change & Urgency

Two industry titans will explore the metamorphosis that is unfolding in health care, driven by innovation and demanded by consumers, that will profoundly transform this space as we know it.

Please click here to view on demand.

Biographies:

Sara Jane Demy, Jeremy Abbate, Ralph Snyderman